Quoin raises up to $104.5M, advances QRX003 regulatory path, reports 2025 net loss $15.8M

Quoin Pharmaceuticals, Ltd.

Closed private placement for up to $104.5M ($16.5M at closing, $88M warrant potential).
FDA grants Fast Track Designation; single Phase 3 study may suffice for NDA; plan to file in 2027.
Orphan Drug Designations for QRX003 in Netherton Syndrome in US and Europe; Rare Pediatric Disease Designation could yield $150-200M PRV.
Pediatric Netherton study expanded to 7 children with sustained skin healing, no adverse events; Peeling Skin study to 6 subjects.
Cash $18.7M at Dec 31, 2025; net loss Q4 $4.3M vs $2.3M YoY; full year $15.8M vs $9.0M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Quoin Pharmaceuticals, Ltd. reported financial results for fourth quarter and fiscal year 2025.

Period: fourth quarter and fiscal year 2025
Result: reported results

Exact text from the filing

Quoin Pharmaceuticals Ltd. (the "Company") announced its fourth quarter and fiscal year 2025 financial results. A copy of the Company's press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Quoin Pharmaceuticals, Ltd. filing history →

Source: SEC EDGAR

accession 0001104659-26-034951

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.